

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE  
SECRETARY OF STATE

CHERYL MYERS  
DEPUTY SECRETARY OF STATE  
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK  
DIRECTOR

800 SUMMER STREET NE  
SALEM, OR 97310  
503-373-0701

**TEMPORARY ADMINISTRATIVE ORDER**  
INCLUDING STATEMENT OF NEED & JUSTIFICATION

**BP 1-2024**

CHAPTER 855  
BOARD OF PHARMACY

**FILED**

02/15/2024 2:39 PM  
ARCHIVES DIVISION  
SECRETARY OF STATE  
& LEGISLATIVE COUNSEL

FILING CAPTION: Temporarily suspends Division 020 Protocol Compendium

EFFECTIVE DATE: 02/29/2024 THROUGH 08/26/2024

AGENCY APPROVED DATE: 02/09/2024

CONTACT: Rachel Melvin  
971-673-0001  
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150  
Portland, OR 97232

Filed By:  
Rachel Melvin  
Rules Coordinator

NEED FOR THE RULE(S):

Proposes to temporarily suspend OAR 855-020-0300 Protocol Compendium.

JUSTIFICATION OF TEMPORARY FILING:

To avoid a conflict with newly adopted OAR 855-115-0345 taking effect on 3/1/2024, the board must temporarily suspend OAR 855-020-0300, effective 2/29/2024 at 11:59PM. Due to Oregon Administrative Rules Database (OARD) filing limitations, the board was unable to send OAR 855-020-0300 to January 24, 2024 rulemaking because the newly added vaccine protocols weren't effective until 2/1/2024. A temporary suspension is necessary because this rule cannot be in effect at the same time as OAR 855-115-0345. All remaining Division 020 rules are currently in the process of being repealed.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

Division 115 Pharmacists Permanent Administrative Order  
[https://www.oregon.gov/pharmacy/Documents/Div\\_115\\_Pharmacists\\_BP\\_16-2023TrackedChanges.pdf](https://www.oregon.gov/pharmacy/Documents/Div_115_Pharmacists_BP_16-2023TrackedChanges.pdf)

SUSPEND: 855-020-0300

RULE SUMMARY: Temporarily suspends OAR 855-020-0300 Protocol Compendium. The board adopted Division 115 Pharmacists rules in August, October and December 2023, which replaces Division 020. This rule needs to be suspended, effective 2/29/2024 to eliminate conflict with the Protocol Compendium permanently adopted in OAR 855-115-0345 effective 3/1/2024. In addition, OAR 855-020-0300 references other rules within Division 020. Since these supporting rules have already been repealed, keeping OAR 855-020-0300 in effect would leave it incomplete and potentially unenforceable.

CHANGES TO RULE:

~~855-020-0300~~  
~~Protocol Compendium~~

A Pharmacist may prescribe, via statewide drug therapy management protocol and according to rules outlined in this Division, an FDA-approved drug and device listed in the following compendium:¶¶

(1) Continuation of therapy including emergency refills of insulin (v. 06/2023);¶¶

(2) Conditions¶¶

(a) Cough and cold symptom management¶¶

(A) Pseudoephedrine (v. 06/2021);¶¶

(B) Benzonatate (v. 06/2021);¶¶

(C) Short-acting beta agonists (v. 06/2021);¶¶

(D) Intranasal corticosteroids (v. 06/2021);¶¶

(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);¶¶

(c) COVID-19 Antigen Self-Test (v. 12/2021); ¶¶

(3) Preventative care¶¶

(a) Emergency Contraception (v. 06/2021);¶¶

(b) Male and female condoms (v. 06/2021);¶¶

(c) Tobacco Cessation, Nicotine Replacement Therapy (NRT) and Non-NRT (v. 06/2022);¶¶

(d) Travel Medications (v. 06/2023);¶¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);¶¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023);¶¶

(g) Contraception (v. 06/2023); and ¶¶

(h) Vaccinations:¶¶

(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 2/2024);¶¶

(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 2/2024);¶¶

(C) Cholera (v. 2/2024); ¶¶

(D) Coronavirus 2019 (v. 2/2024); ¶¶

(E) Haemophilus Influenza type b (v. 2/2024)¶¶

(F) Hepatitis A containing vaccines (v. 2/2024); ¶¶

(G) Hepatitis B containing vaccines (v. 2/2024); ¶¶

(H) Human Papillomavirus (v. 2/2024); ¶¶

(I) Influenza – Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 2/2024); ¶¶

(J) Influenza – Live Attenuated Influenza Vaccine 2023-24 (v. 2/2024); ¶¶

(K) Japanese Encephalitis (v. 2/2024); ¶¶

(L) Meningococcal containing vaccines (v. 2/2024); ¶¶

(M) Measles Mumps & Rubella containing vaccines (v. 2/2024); ¶¶

(N) Pneumococcal (v. 2/2024); ¶¶

(O) Polio (v. 2/2024); ¶¶

(P) Rabies (v. 2/2024); ¶¶

(Q) Respiratory Syncytial Virus (v. 2/2024);¶¶

(R) Tetanus Diphtheria containing vaccines (v. 2/2024);¶¶

(S) Typhoid (v. 2/2024); ¶¶

(T) Varicella containing vaccines (v. 2/2024);¶¶

(U) Yellow fever (v. 2/2024); ¶¶

(V) Zoster (v. 2/2024).¶¶

[Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.696